Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by MML Investors Services LLC

MML Investors Services LLC boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 24.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 4,338 shares of the medical equipment provider’s stock after purchasing an additional 857 shares during the period. MML Investors Services LLC’s holdings in Lantheus were worth $476,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. Nkcfo LLC acquired a new stake in Lantheus during the second quarter worth approximately $47,000. UMB Bank n.a. grew its stake in Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after acquiring an additional 126 shares during the period. Kathleen S. Wright Associates Inc. acquired a new position in Lantheus in the 3rd quarter valued at $51,000. Finally, GAMMA Investing LLC lifted its stake in shares of Lantheus by 45.5% during the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Truist Financial restated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities cut their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Stock Performance

LNTH opened at $89.29 on Monday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a 50 day moving average price of $96.17 and a 200 day moving average price of $98.45. The company has a market cap of $6.21 billion, a PE ratio of 14.86 and a beta of 0.45.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.